Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca plc (ADR) (AZN): Is This Purchase a Game-Changer?

Page 1 of 2

London-based pharmaceutical giant AstraZeneca plc (ADR) (NYSE:AZN) recently announced that it had agreed to purchase U.S.-based lung-drug manufacturer Pearl Therapeutics for at least $1.1 billion. The private firm is noted for its next-generation inhaler technology that could prove key in the fight to control chronic lung conditions like COPD as well as certain forms of childhood and adult asthma. Although the market’s reaction to the deal has generally been positive, many observers wonder whether AstraZeneca is doing enough to prepare for the knock-on effects of a weak development pipeline and looming patent expirations.

AstraZeneca plc (ADR) (NYSE:AZN)

Since Pearl is a privately held company, investors cannot expect to receive an arbitrage premium from this deal. However, this does not mean that the merger lacks value. On the contrary, the successful integration of Pearl’s operations could put AstraZeneca plc (ADR) (NYSE:AZN) on the path to lung-drug dominance for years to come. Investors would do well to take a closer look.

AstraZeneca and the Competition

As a global pharmaceutical firm with a huge research and development apparatus, AstraZeneca competes with some of the biggest names in the business. For the purposes of this comparison, it would be wise to measure AstraZeneca plc (ADR) (NYSE:AZN) against fellow British drug-maker GlaxoSmithKline plc (ADR) (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK). All three of these companies engage in similar activities and have outsized influence on the global drug industry.

Relative to its peers, AstraZeneca seems rather inconsequential. The company’s $63 billion market capitalization is less than half the size of GSK’s valuation and nearly 60 percent smaller than that of Merck. However, the firm is a bit more profitable than the other two companies in this comparison. In 2012, AstraZeneca plc (ADR) (NYSE:AZN) took in about $5.7 billion on total revenues of $27 billion. This made for a profit margin of well over 20 percent. During the same period, Merck & Co., Inc. (NYSE:MRK) reported earnings of $6 billion on revenues of just over $46 billion. GSK earned $6.8 billion on a gross of $42 billion.

AstraZeneca plc (ADR) (NYSE:AZN) has a fairly stable balance sheet and a decent financial outlook. As of its most recent report, the company had about $8 billion in cash on hand and a little over $10 billion in long-term debt. Comparable figures for Merck came in at $16 billion and $21 billion. Meanwhile, GSK’s debt load of $31 billion dwarfs its $6.3 cash reserve. All three of these firms have adequate, proportional cash flow figures.

How the Deal Happened

The merger agreement between AstraZeneca and Pearl has a two-step structure that could provide the larger company with some protection against a potential flame-out. According to the text of the deal, AstraZeneca plc (ADR) (NYSE:AZN) will issue a guaranteed cash payment of about $560 million to Pearl’s private shareholders. If the newly subsumed company is able to create viable, marketable products that achieve pre-determined sales and revenue metrics, AstraZeneca will provide a second tranche of nearly $600 million to the company’s shareholders. Since AstraZeneca has not commented publicly on the substance of these metrics, it is difficult to determine whether they are realistic.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!